Expressing support for the designation of September 30, 2025, as "Rare Cancer Day" to highlight the challenges patients with rare cancers face and to raise awareness and support efforts to improve early diagnosis and treatment.

Legislative Summary: H.Res. 732

Overview

H.Res. 732 is a House Resolution introduced in the 119th Session of the U.S. Congress. The primary purpose of this resolution is to advocate for the designation of September 30, 2025, as "Rare Cancer Day." The resolution seeks to bring national attention to the unique challenges faced by patients diagnosed with rare cancers, focusing specifically on the difficulties of early diagnosis and the need for advanced treatment options.

Purpose and Intent

The resolution highlights a critical gap in oncology: while common cancers often have established screening protocols and treatment pathways, rare cancers often go undetected or untreated due to a lack of awareness and scientific data.

By designating a specific day of awareness, the House aims to:
* Increase Public Awareness: Educate patients on recognizing rare cancer symptoms.
* Support Clinicians: Encourage healthcare providers to recognize unusual symptoms more quickly to reduce the time to diagnosis.
* Promote Research: Call for increased scientific study and funding to develop effective treatments and cures.

Key Provisions and Acknowledgments

As a House Resolution, this bill is a formal expression of the House's will and does not create new laws or mandate specific government actions. However, it officially records the following positions:

• Recognition of Prevalence: Acknowledges that approximately 1 in 5 cancer patients in the U.S. has a rare cancer and notes that all pediatric cancers are classified as rare.
• Impact on Survival: Recognizes that rare cancers account for 25% of all cancer deaths and typically have lower 5-year survival rates than common cancers.
• Call for Action:
  • Supports the dedication of funding for research into cures and treatments.
  • Encourages partnerships between the government, medical professionals, and the scientific community to improve diagnostic accuracy.

Who is Affected?

The resolution primarily impacts and advocates for:
* Patients and Families: Specifically those dealing with rare or pediatric cancers who face longer diagnostic windows and limited treatment options.
* Medical Professionals: By encouraging a shift toward higher awareness of rare oncology symptoms.
* Research Institutions: By signaling legislative support for funding and partnerships focused on rare disease research.

Procedural Status

• Introduced: September 17, 2025
• Current Status: Referred to the House Committee on Energy and Commerce.
• Sponsorship: The resolution features bipartisan support, with co-sponsors including Representatives Mike Kelly, Debbie Wasserman Schultz, Brian Fitzpatrick, and Debbie Dingell.